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ABSTRACT
Background and aim It is useful, for theoretical and practical reasons, to be able to specify functions for continuous
abstinence over time in smoking cessation attempts. This study aimed to ﬁnd the best-ﬁtting models of mean proportion
abstinent with different smoking cessation pharmacotherapies up to 52weeks from the quit date.Methods We searched
the Cochrane Database of Systematic Reviews to identify randomized controlled trials (RCTs) of pharmacological treat-
ments to aid smoking cessation. For comparability, we selected trials that provided 12 weeks of treatment. Continuous
abstinence rates for each treatment at each follow-up point in trials were extracted along with methodological details of
the trial. Data points for each pharmacotherapy at each follow-up point were aggregated where the total across contrib-
uting studies included at least 1000 participants per data point. Continuous abstinence curves were modelled using a
range of different functions from the quit date to 52-week follow-up. Models were compared for ﬁt using R2 and Bayesian
information criterion (BIC).Results Studiesmeeting our selection criteria covered three pharmacotherapies [varenicline,
nicotine replacement therapy (NRT) and bupropion] and placebo. Power functions provided the best ﬁt (R2 > 0.99, BIC
< 17.0) to continuous abstinence curves from the target quit date in all cases except for varenicline, where a logarithmic
function described the curve best (R2 = 0.99, BIC = 21.2). At 52weeks, abstinence rates were 22.5% (23.0%modelled) for
varenicline, 16.7% (16.0% modelled) for bupropion, 13.0% (12.4% modelled) for NRT and 8.3% (8.9% modelled) for
placebo. For varenicline, bupropion, NRT and placebo, respectively, 55.9, 65.0, 62.3 and 56.5% of participants who were
abstinent at the end of treatment were still abstinent at 52 weeks. Conclusions Mean continuous abstinence rates up to
52 weeks from initiation of smoking cessation attempts in clinical trials can be modelled using simple power functions for
placebo, nicotine replacement therapy and bupropion and a logarithmic function for varenicline. This allows accurate
prediction of abstinence rates from any time point to any other time point up to 52 weeks.
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INTRODUCTION
Continuous abstinence rates after initiation of a smoking
quit attempt follow a negatively decelerating curve over
time [1]. This is a common pattern with attempts to stop
engaging in addictive behaviours [2]. It is useful to be able
to model the curve relating continuous abstinence to time
from quit attempt initiation in order to understand the
processes underlying smoking relapse and the impact of
treatments on these processes, as well as for the more
practical goal of predicting long-term abstinence rates from
short-term outcomes. This paper synthesizes evidence
from clinical trials of pharmacotherapies in smoking cessa-
tion to derive best-ﬁtting, up-to-date models of mean con-
tinuous abstinence rates as a function of time since the
quit attempt started.
Results of clinical trials and cohort studies suggest that
with unaided quit attempts, only approximately a quarter
of those trying to quit remain abstinent for a week, fewer
than one in 10 remain abstinent for 6 months and fewer
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than one in 20 remain abstinent at 1 year [1]. Continuous
abstinence curves for smokers receiving support for quit-
ting can be derived for a number of individual studies with
multiple follow-up points [3–5], but functions describing
the shape of the continuous abstinence curve over time
have not been speciﬁed thus far.
Some studies have speciﬁcally addressed the question
of whether relapse rates increase when treatment is termi-
nated. A recent synthesis of evidence from trials of
varenicline showed a higher relapse rate from the end of
12 weeks of treatment to 24-week follow-up than for pla-
cebo [6], but the difference had disappeared by 52-week
follow-up. Studies exploring the long-term impact of nico-
tine replacement therapy (NRT) have found diminishing
efﬁcacy in terms of absolute percentage differences from
placebo with increased time since quit attempt initiation
[7,8]. None of these studies sought to model the shape of
the relapse curve, however.
Modelling the shape of continuous abstinence curves in
smoking cessation is important for several reasons: (1) if
the continuous abstinence curves follow a well-deﬁned
and relatively simple mathematical formula, it would allow
for prediction of abstinence rates from any time-point to
any future time-point, which is important clinically and
when assessing health impact [9]. (2) The shape of the
curve may help in understanding what drives resumption
of smoking at different time-points. It has been suggested
that factors affecting early resumption of smoking may
differ in kind from those driving later resumption [10].
This, in turn, has implications for interventions that may
be effective at different time-points. (3) If the curves
follow different shapes with different pharmacotherapies,
it suggests that these may operate differentially on factors
inﬂuencing resumption of smoking. For example, if the
curve shows an inﬂection downwards post-treatment for
a given pharmacotherapy, it suggests either that it is not
adequately addressing chronic factors that lead to smoking
resumption or that the treatment duration was too short.
When seeking to study continuous abstinence curves it
is important to have high-quality data with high follow-up
rates. Prospective cohort studies can provide valuable in-
formation, but often there are limitations with regard to
loss to follow-up and inconsistencies in treatment duration
that make it difﬁcult to make meaningful comparisons.
With greater control over treatment conditions, higher re-
tention rates and data collection occurring at multiple
time-points, randomized controlled trials (RCTs) provide
an opportunity to examine continuous abstinence follow-
ing pharmacological interventions for smoking cessation
in greater detail. This study therefore aggregated data from
high-quality RCTs to describe the shape and parameters of
mean continuous abstinence curves associated with differ-
ent smoking cessation pharmacotherapies. Speciﬁcally, we
aimed to address the following research questions:
1 What functions best characterize the shape of mean
continuous abstinence curves over the ﬁrst year follow-
ing quit attempts in smoking cessation RCTs?
2 Do these differ with different pharmacotherapies?
METHOD
Search strategy and study selection
Details of our study search and selection procedure are pro-
vided in Fig. 1. We searched the Cochrane Database of
Systematic Reviews in the Cochrane Library (from 1990
to March 2017) for reviews with ‘smoking’ in the title, ab-
stract or keyword ﬁelds. The results were assessed by three
authors (J.M., H.U., R.W.) in order to identify reviews focus-
ing on pharmacological treatments for smoking cessation;
seven were identiﬁed as being appropriate for this study
[11–17]. The reference lists of these reviews provided a
pool of potential studies for inclusion in the present study.
Supporting information, Appendix S1 contains an Excel ﬁle
providing details of all studies considered in case readers
wish to undertake their own analyses.
We included RCTs that compared continuous absti-
nence rates between pharmacological interventions,
between one intervention and a placebo or between differ-
ent pharmacotherapy doses and a placebo. We limited our
Figure 1 Flow diagram of search strategy and study selection
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search to articles published since 1990 because we consid-
ered trial reporting and conduct to have improved since
then, with agreed reporting criteria for trials such as Con-
solidated Standards of Reporting Trials (CONSORT) being
more widely used [18]. Trials that compared a pharmaco-
logical intervention with ‘standard care’ were excluded, as
were studies that focused on a reduction in cigarette con-
sumption, or setting of quit dates rather than abstinence.
We also excluded trials of combinations of different phar-
macotherapies. Trials that reported only point prevalence
(as opposed to continuous) abstinence rates were excluded,
because it was not possible to determine whether absti-
nence was the result of the initial quit attempt. Trials with
a sample size < 10 participants were also excluded, be-
cause it was judged that these would have been pilot or
feasibility trials. We did not exclude any studies by virtue
of heaviness of smoking or other smoker characteristics,
but the large majority of studies set a minimum of 10 or
more cigarettes per day for inclusion.
Due to the stringent criteria of Cochrane Reviews, all
included RCTs were considered to be of acceptable stan-
dard. Studies awaiting assessments and ongoing studies
were included where results were available.
Data extraction
RCTs that met the criteria detailed above were extracted
from the relevant Cochrane Reviews. From these trials
we extracted information on sample size, pharmacother-
apies used, length of pharmacotherapy intervention, start
point of follow-up, duration of follow-up and the percent-
age of participants who were continuously abstinent over
time in each condition from a given start point to each
follow-up point. Other data extracted from the trials in-
cluded year of publication, year of trial start and country
of origin.
Analyses
There was signiﬁcant heterogeneity across study samples,
methods and presentation of results. In order to standard-
ize results for comparison across different pharmacother-
apies while maximizing data available for the estimation
of continuous abstinence curves, we selected studies that
had used a 12-week treatment programme; this was the
modal andmedian duration of treatments in the 98 studies
[4,5,19–115] from which we extracted data. We used
Microsoft Excel 2013 to plot the mean continuous absti-
nence rates weighted by sample size for follow-up points
where there were aggregated data from a minimum of
1000 participants for all treatment groups. The resulting
graphs describe the mean continuous abstinence rates as-
sociated with the different pharmacotherapies, displaying
curves from the start of treatment to 52 weeks (the longest
follow-up for which the required data were available). For
each treatment group, we compared four function classes
(linear, exponential, logarithmic, and power) and ﬁtted
the one with the highest R2. To handle zero values in the
case of power functions, the starting time-point was
0.1 week, representing less than 1 day of abstinence. Model
selection was conﬁrmed by comparing the Bayesian
information criterion (BIC) of each curve (calculated in
Stata version 15), with lower BIC values indicating better
model ﬁt.
To check how far the relapse curves from the aggre-
gated data matched within-study changes in continuous
abstinence rates over time, we superimposed lines between
consecutive pairs of time-points with each of the three larg-
est studies, including where there were data available for
additional time-points for each pharmacotherapy, onto
our continuous abstinence curves to assess whether the
curves were a reasonable ﬁt.
RESULTS
Our search and selection procedure (Fig. 1) identiﬁed
43 trials eligible for inclusion in the present analysis.
Their characteristics are summarized in Table 1. A total of
23 trials used varenicline [4,69–71,74,77,78,80,84–
89,91,93,95,98,101,103,109,110,115], 12 used bupropion
[4,50,56,63,64,66,69,70,85,90,95,101] and 15 used
NRT [4,22,25,28–30,32,48,49,72,88,90,100,105,113],
with some studies using more than one of these
pharmacotherapies in different treatment groups. A
placebo was used as a control in 38 of these trials
[4,22,25,28–30,32,48–50,56,63,64,66,69–72,74,77,78,84–
87,89,91,93,95,98,100,101,103,105,109,110,113,115], and
a further two trials provided only placebo data due to the
active comparator failing to meet criteria for inclusion
[45,104].
Figure 2 shows the continuous abstinence curves
from the quit date to 52-week follow-up for varenicline,
bupropion, NRT and placebo. An interactive version of this
graph is available in Supporting information, Appendix S2.
The shape of the continuous abstinence curve was similar
throughout the different pharmacotherapies (including
placebo), with relapse rates highest in the initial 3–4weeks
and slowly tapering off after the end of treatment. Compar-
ison of model selection statistics (Table 2) indicated that
continuous abstinence data for bupropion, NRT and
placebo could best be described by a power function
(all R2 > 0.99), while the best-ﬁtting curve for varenicline
was logarithmic (R2 = 0.99). Equations for the best-ﬁtting
curve for each pharmacotherapy are shown in Fig. 2.
The power function for varenicline also ﬁtted well
(Supporting information, Fig. S1: R2 = 0.94), but it
overestimated the 52-week abstinence rate.
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Table 1 Characteristics of included studies.
Authors Year
Country of
origin Special samples
Pharmacotherapies
(italics indicate those not
included in modelling)
n (in order of stated
pharmacotherapies)
Follow-up
points
(weeks)
Sachs et al. [22] 1993 Sweden – NRT patch, placebo 110, 110 6, 12, 18,
26, 52
Imperial Cancer Research
fund General practice
research group [25]
1994 UK – NRT patch, placebo 842, 844 12, 52
Gourlay et al. [29] 1995 Australia – NRT patch, placebo 315, 314 4, 8, 12,
26
Stapleton et al. [28] 1995 UK – NRT patch, placebo 800, 400 3, 6, 12,
26, 52
Campbell et al. [30] 1996 UK Hospital patients NRT patch, placebo 115, 119 12, 52
Sønderskov et al. [32] 1997 Denmark – NRT patch, placebo 251, 142 4, 8, 12,
26
Wong et al. [45] 1999 USA – Naltrexone, placebo 23, 26 1, 2, 3, 4,
6, 8, 10,
12, 24
Tønnesen et al. [49] 2000 Denmark Lung clinic
attenders
NRT patch, NRT
inhaler, placebo
104, 118, 109 2, 6, 12,
36, 52
Wallström et al. [48] 2000 Sweden – NRT sublingual tablet,
placebo
123, 124 6, 12, 24,
52
Tashkin et al. [50] 2001 USA Chronic obstructive
pulmonary disease
Bupropion, placebo 129, 149 5, 6, 7,
10, 12,
26
Trial ZYB40001 [56] 2003 Canada – Bupropion, placebo 141, 143 7, 12
Evins et al. [64] 2005 USA Schizophrenics Bupropion, placebo 25, 28 12
Wagena et al. [63] 2005 Netherlands At risk for chronic
obstructive
pulmonary disease
Bupropion, nortriptyline,
placebo
86, 80, 89 12, 26
Gonzales et al. [69] 2006 USA – Varenicline, bupropion,
placebo
352, 329, 344 12, 24,
52
Jorenby et al. [70] 2006 USA – Varenicline, bupropion,
placebo
344, 342, 341 12, 24,
52
Oncken et al. [71] 2006 USA – Varenicline, placebo 518, 129 7, 12, 24,
52
Rigotti et al. [66] 2006 USA Hospitalized with
acute cardiovascular
disease
Bupropion, placebo 124, 123 12, 52
David et al. [72] 2007 UK – NRT patch, placebo 370, 371 12, 24
Nakamura et al. [74] 2007 Japan – Varenicline, placebo 465, 154 12, 24,
52
Tsai et al. [77] 2007 Korea, Taiwan – Varenicline, placebo 126, 124 12, 24
Aubin et al. [80] 2008 UK, USA,
Belgium,
France,
Netherlands
– Varenicline, NRT patcha 376, 370 12, 52
Niaura et al. [78] 2008 USA – Varenicline, placebo 157, 155 7, 12, 24,
52
Wang et al. [84] 2009 China,
Singapore,
Thailand
– Varenicline, placebo 158, 161 12, 24
Fagerström et al. [87] 2010 Norway,
Sweden
– Varenicline, placebo 213, 218 12, 26
Fagerström et al. [89] 2010 6 Asian
countries
– Varenicline, placebo 447, 446 12, 24
(Continues)
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At the end of treatment, 45.1% (41.2%modelled; loga-
rithmic curve) of participants treated with varenicline,
26.3% (24.6% modelled) of those treated with bupropion,
20.8% (20.2% modelled) of those treated with NRT and
16.2% (15.7% modelled) of those treated with placebo
were still abstinent. By 52 weeks, abstinence rates had
fallen to 22.5% (23.0% modelled) for varenicline, 16.7%
(16.0% modelled) for bupropion, 13.0% (12.4% modelled)
for NRT and 8.3% (8.9% modelled) for placebo. A total of
49.8% (55.9%modelled) of those treated with varenicline,
63.4% (65.0% modelled) of those treated with bupropion,
62.5% (61.3% modelled) of those treated with NRT and
51.5% (56.5% modelled) of those treated with placebo
whowere abstinent at the end of treatment were still absti-
nent at 52 weeks.
Superimposing lines drawn between continuous absti-
nence rates from consecutive follow-up points within the
three largest studies for each pharmacotherapy showed a
good ﬁt to the modelled curves (Supporting information,
Fig. S2).
DISCUSSION
There were sufﬁcient data to enable reliable estimation of
mean continuous abstinence rates for end of treatment
(12-week post-quit date), 26- and 52-week time-points.
Table 1. (Continued)
Authors Year
Country of
origin Special samples
Pharmacotherapies
(italics indicate those not
included in modelling)
n (in order of stated
pharmacotherapies)
Follow-up
points
(weeks)
Hays et al. [85] 2010 USA – Varenicline, bupropion,
placebo
692, 669, 684 12
Rigotti et al. [86] 2010 15 countries Stable
cardiovascular
disease
Varenicline, placebo 355, 359 12, 24,
52
Tsukahara et al. [88] 2010 Japan – Varenicline, NRT patch 16, 16 12, 24
Bolliger et al. [93] 2011 11 countries – Varenicline, placebo 390, 198 12, 24
Tashkin et al. [91] 2011 USA, Spain,
France, Italy
Mild/moderate
chronic obstructive
pulmonary disease
Varenicline, placebo 250, 254 12, 24,
52
Wittchen et al. [90] 2011 Germany – Bupropion, NRT 108, 105 52
Xenakis et al. [95] 2011 USA – Varenicline, bupropion,
placebo
696, 671, 685 12, 52
Rennard et al. [98] 2012 14 countries – Varenicline, placebo 493, 166 12, 24
Tønnesen et al. [100] 2012 Denmark,
Germany
– NRT mouth spray,
placebo
318, 161 4, 6, 8,
12, 16,
20, 24,
52
Anthenelli et al. [103] 2013 8 countries Major depression Varenicline, placebo 256, 269 12, 24,
52
Bullen et al. [105] 2013 New Zealand – NRT patch, e-cigarettes,
placebo
295, 289, 73 4, 12, 24
Caponnetto et al. [104] 2013 Italy – E-cigarettes, placebo 200, 100 12, 52
Cinciripini et al. [101] 2013 USA – Varenicline, bupropion,
placebo
86, 102, 106 12, 24,
36
Gonzales et al. [110] 2014 8 countries – Varenicline, placebo 249, 245 12, 24,
52
Trial NCT01347112
[109]
2014 USA Alcoholics Varenicline, placebo 16, 17 12, 24
O’Brien et al. [113] 2015 New Zealand With and without
mental illness
NRT patch, e-cigarettes,
placebo
260, 250, 61 24
Anthenelli et al. [4] 2016 16 countries With and without
psychiatric disorders
Varenicline, bupropion,
NRT patch, placebo
2037, 2034,
2038, 2035
12, 24
Eisenberg et al. [115] 2016 Canada Hospitalized patients
with acute coronary
syndrome
Varenicline, placebo 151, 151 4, 12, 24
All studies involved 12weeks of pharmacotherapy. aNicotine replacement therapy (NRT) patch was administered for 10weeks. so results were not included in
analyses.
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The shape of the function relating these to time could best
be modelled by power functions for placebo, NRT and
bupropion and a logarithmic function for varenicline.
Being able to describe continuous abstinence curves
using a simple function, in theory, provides a basis for
predicting relapse from one time-point to any other time-
point. This is useful when one only has short-term follow-
up data available, or when interpolating back from long-
term data. In UK stop-smoking services, for example, it is
common to use 4- or 12-week abstinence rates in targets
because limited resources make it impracticable to collect
accurate longer-term data. Unfortunately, there were not
sufﬁcient data to estimate continuous abstinence rates
prior to 12 weeks, so it is possible that more complex func-
tions during the treatment period may have been missed.
However, wewere able to provide precise estimates of mean
relapse rates following end of treatment for the different
pharmacotherapies.
The ﬁnding that a single function starting at the quit
date was able to capture abstinence rates at the end of
treatment, as well as 26- and 52-week abstinence rates,
suggests that a single relapse process is in operation during
and after treatment. This appears to conﬂict with studies
suggesting that different processes may be in operation.
However, it remains possible that different processes are
in operation, but their combined effects remain the same.
This is a topic that merits further investigation.
We did not see evidence for a point of inﬂection in the
curves at the end of treatment with the active pharmaco-
therapies, which also suggests that by 12 weeks from the
quit date these pharmacotherapies have had whatever ef-
fect they are going to have. This accords with ﬁndings from
trials with NRT which have not found clear evidence for a
beneﬁt of extending treatment beyond 12 weeks [5,7]. It
conﬂicts with ﬁndings from a large RCT with varenicline,
which showed a beneﬁt from extending treatment for a
Figure 2 Continuous abstinence rates with best-ﬁtting curves estimated from continuous abstinence rates from randomized controlled trials (RCTs)
of 12-week treatment with smoking cessation pharmacotherapies. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
Table 2 Model selection statistics for continuous abstinence curves from 0 to 52 weeks.
Varenicline Bupropion NRT Placebo
R2 BIC R2 BIC R2 BIC R2 BIC
Linear 0.669 37.01 0.516 39.60 0.499 40.12 0.503 40.44
Exponential 0.817 31.53 0.619 31.97 0.613 30.73 0.678 28.78
Logarithmic 0.994 21.16 0.984 25.88 0.980 27.23 0.980 27.55
Power 0.940 26.69 0.991 16.92 0.996 11.75 0.998 7.29
BIC = Bayesian information criterion; NRT = nicotine replacement therapy.
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further 12 weeks [116]. However, this beneﬁt appeared to
occurwith participants who had notmanaged to attain ab-
stinence early on and had only been abstinent for a short
while when the 12-week course of treatment ended
[117]. This suggests an optimum treatment regimen for
varenicline of 12 weeks if smokers are able to abstain dur-
ing the ﬁrst week, but 24 weeks if they only manage to ab-
stain after a few weeks—the aim being to ensure that they
receive approximately 12 weeks of pharmacotherapy from
the point at which they initiate abstinence.
Of the four functions we ﬁtted to the data, power func-
tions provided the best ﬁt for continuous abstinence from
all treatments with the exception of varenicline, which
was better described by a logarithmic curve. This difference
was driven by the higher 12-week abstinence rate observed
in participants treated with varenicline. Methodological
differences between trials of varenicline and other pharma-
cotherapies may account for at least some of this variance.
Varenicline trials typically measure continuous abstinence
from week 9 rather than from the target quit date, so the
ﬁgure may be somewhat inﬂated, given that varenicline re-
cruits smokers into abstinence for several weeks after the
target quit date [118]. The results suggest that there is
no beneﬁt in recruiting these additional smokers into absti-
nence, as they aremore likely to relapse between the end of
treatment and 52-week follow-up compared with those
treated with other pharmacotherapies.
This study had several limitations. First, there was sub-
stantial heterogeneity in trial methods and study samples
which may have introduced noise to the data points. Sec-
ondly, there were only sufﬁcient data to plot abstinence
rates for 12, 24 and 52 weeks after the start of treatment.
It would have been useful to have data available on a
greater number of time-points to incorporate into our con-
tinuous abstinence curves, particularly in the early weeks
where relapse rates were very high. Thirdly, we were only
able to include three pharmacotherapies and placebo in
our analysis. Therewere insufﬁcient data available on com-
bination NRT and other popular and emerging pharmaco-
logical aids to smoking cessation, such as e-cigarettes,
nortriptyline and cytisine, and it is possible that the contin-
uous abstinence curves associated with these treatments
may differ from those observed here. Fourthly, we pre-
speciﬁed a small number of functions, and it may be that
another function would be more appropriate. Although
the ﬁt of the selected function was very high, there was
only a small number of follow-up points. With more
follow-up points, a better-ﬁtting function might emerge.
Fifthly, while a power function provided a very good ﬁt in
most cases, the y value is inﬁnite at x = 0 rather than
100%, so the starting point for time has to be a number
above 0. We chose 0.1 weeks (representing less than
1 day) as a value close to 0, and this provided a very close
ﬁt to the data. However, a more mathematically sound
function with a similar shape may be preferable. Finally,
we limited follow-up to 52 weeks because of the scarcity
of data points after that point. Studies with longer-term
follow-up have been conducted, and these suggest that ap-
proximately 30% of those who abstain for 52weeks relapse
at some point within the next 10 years [7]. This suggests
that the power function, which has a very shallow slope af-
ter 52 weeks, may be an adequate ﬁt to the longer-term
continuous abstinence curve.
In conclusion, this study indicates that a power func-
tion, or a function very close to it in shape, provides a very
close ﬁt to mean continuous abstinence from smoking in
studies of smokers trying to quit using placebo, nicotine
replacement therapy or bupropion. For varenicline, a loga-
rithmic function appears to provide a better ﬁt.
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